Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A injection in the masseter muscle for reducing bite force in asymptomatic bruxism
TCTR20201105003Phase 3Enrolling by invitation
- Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in bruxism, sponsored by Faculty of Medicine Siriraj Hospital, Mahidol University. Primary endpoint: Duration of action of botulinum toxin A injection in masseteric muscle to reduce bite force at 12 months. Started Aug 2020; status: enrolling by invitation.
02
Drugs
botulinum toxin type A
03
Conditions
bruxism
Beyond the preview
Go deeper on TCTR20201105003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201105003.